Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.
Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.
Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.
Exact Sciences Corp. (EXAS) presented six abstracts at Digestive Disease Week 2024, focusing on improving colorectal cancer screening rates. The company showcased data on Cologuard®, a non-invasive screening test, and the upcoming Cologuard Plus™. These advancements aim to enhance patient outcomes by emphasizing effective detection rates and user convenience. The research can potentially address the critical gap in colorectal cancer screening in the U.S.
Exact Sciences Corp. will participate in the BofA Securities Health Care Conference in Las Vegas, with a fireside chat scheduled for May 15, 2024. Investors are invited to join the webcast available on the company's website.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
